148258-27-9

Usage

Uses

Used in Pharmaceutical Industry:
6-(ChloroMethyl)nicotinic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its antimicrobial and antioxidant properties make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
6-(ChloroMethyl)nicotinic acid is used as a building block in the creation of agrochemicals, contributing to the development of effective products for agricultural applications.
Used in Medical Research:
6-(ChloroMethyl)nicotinic acid is used as a subject of interest in medical research for its potential role in the treatment of neurological disorders and cardiovascular diseases, highlighting its importance in drug development and therapeutic innovation.

Upstream product

• 3222-47-7 6-methylnicotinic acid 
• 49668-90-8 methyl 6-(chloromethyl)pyridine-3-carboxylate 

Downstream Products

• 205313-13-9 6-((E)-2-{3-[(R)-3-[2-(1-Hydroxy-1-methyl-ethyl)-phenyl]-1-(1-methoxycarbonylmethyl-cyclopropylmethylsulfanyl)-propyl]-phenyl}-vinyl)-nicotinic acid 
• 125439-36-3 6-{4-[3-(1H-Tetrazol-5-yl)-propoxy]-phenoxymethyl}-nicotinic acid 

Relevant academic research and scientific papers

THIAZOLE DERIVATIVE

(Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic grou

Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

The present invention is directed to substituted nicotinamides and analogs thereof, represented by Formula V: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Ar′ and Ar are independently optionally substituted aryl or optionally substituted heteroaryl, provided that the ring structure of said optionally substituted heteroaryl comprises not more than two nitrogen atoms; and R11 is hydrogen; or alkyl, cycloalkyl, aryl or heteroaryl, each of which is optionally substituted. The present invention also relates to the discovery that compounds having Formula V are activators of caspases and inducers of apoptosis. Therefore, the compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair

The structure-activity relationship of a series of styrylpyridine analogs of MK-0476 (montelukast, Singular) is described. This work has led to the identification of a number of potent and orally active cysLT1 receptor (LTD4 receptor) antagonists including 2ab (L-733,321) as an optimized candidate.